Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle et al. · Journal of Clinical Oncology · 2019
PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). KEYNOTE-240 evaluated the efficacy and safety of pembrolizumab in this population. PATIENTS AND METHODS This randomized, double-blind, phase III study was conducted at 119 medical centers in 27 countries. Eligible patients with advanced HCC, previously treated with sorafenib, were randomly assigned at a two-to-one ratio to receive pembrolizumab plus best supportive care (BSC) or placebo plus BSC. Primary end points were overall survival (OS) and progression-free survival (PFS; one-sided significance thresholds, P = .0174 [final analysis] and P = .002 [first interim analysis], respectively). Safety was assessed in all patients who received ≥ 1 dose of study drug. RESULTS Between May 31, 2016, and November 23, 2017, 413 patients were randomly assigned. As of January 2, 2019, median follow-up was 13.8 months for pembrolizumab and 10.6 months for placebo. Median OS was 13.9 months (95% CI, 11.6 to 16.0 months) for pembrolizumab versus 10.6 months (95% CI, 8.3 to 13.5 months) for placebo (hazard ratio [HR], 0.781; 95% CI, 0.611 to 0.998; P = .0238). Median PFS for pembrolizumab was 3.0 months (95% CI, 2.8 to 4.1 months) versus 2.8 months (95% CI, 2.5 to 4.1 months) for placebo at the first interim analysis (HR, 0.775; 95% CI, 0.609 to 0.987; P = .0186) and 3.0 months (95% CI, 2.8 to 4.1 months) versus 2.8 months (95% CI, 1.6 to 3.0 months) at final analysis (HR, 0.718; 95% CI, 0.570 to 0.904; P = .0022). Grade 3 or higher adverse events occurred in 147 (52.7%) and 62 patients (46.3%) for pembrolizumab versus placebo; those that were treatment related occurred in 52 (18.6%) and 10 patients (7.5%), respectively. No hepatitis C or B flares were identified. CONCLUSION In this study, OS and PFS did not reach statistical significance per specified criteria. The results are consistent with those of KEYNOTE-224, supporting a favorable risk-to-benefit ratio for pembrolizumab in this population.
Cited by 1,785 works. doi:10.1200/jco.19.01307
Authors
- Richard S. Finn
- Baek‐Yeol Ryoo
- Philippe Merle
- Masatoshi Kudo
- Mohamed Bouattour
- Ho Yeong Lim
- Valeriy Vladimirovich Breder
- Julien Edeline
- Yee Chao
- Sadahisa Ogasawara
- Thomas C. C. Yau
- Marcelo Garrido S
- Stephen Lam Chan
- Jennifer Jane Knox
- Bruno Daniele
- Scot Ebbinghaus
- Erluo Chen
- Abby B. Siegel
- Andrew Xiuxuan Zhu
- Ann‐Lii Cheng
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- Discrete Sequential Boundaries for Clinical Trials
- Transection of the oesophagus for bleeding oesophageal varices
- Sorafenib in Advanced Hepatocellular Carcinoma
- Comparative analysis of two rates
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial